Publicado 19/09/2014 14:52
- Comunicado -

New Xultophy® (IDegLira) Data Show Rapid and Predictable Glycaemic Improvements in People with Type 2 Diabetes (y 2)

4. Gough S, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes, Lancet Diabetes Endocrinology. Epub ahead of print. 2 September 2014. DOI:# 10.1016/S2213-8587(14)70174-3.

Further information:


Media:
Katrine Sperling +45-4442-6718 krsp@novonordisk.com

Investors:
Kasper Roseeuw Poulsen +45-3079-4303 krop@novonordisk.com
Jannick Lindegaard Denholt +45-3079-8519 jlis@novonordisk.com
Daniel Bohsen +45-3079-6376 dabo@novonordisk.com
Frank Daniel Mersebach (US) +1-609-235-8567 fdni@novonordisk.com

Video:
http://www.multivu.com/players/English/72762519-novo-nordisk...

Contenido patrocinado